Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Photodynamic therapy for treatment of solid tumors--potential and technical challenges.

Technology in cancer research & treatment·2008

Same author

Reading.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2007

Same author

Biomedical entrepreneurship should be the fourth mission of all healthcare organizations.

MedGenMed : Medscape general medicine·2007

Same author

The 12-step innovation roadmap: how to analyze and prioritize new business ideas.

Physician executive·2006

Same author

The surgical management of oral cancer.

Otolaryngologic clinics of North America·2006

Same author

Biophotonic and other physical methods for characterizing oral mucosa.

Otolaryngologic clinics of North America·2005

Search research articles

Related Experiment Video

Updated: May 14, 2026

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Combination Products And the FDA: Issues and Answers.

Howard Manresa, Arlen D Meyers

Biotechnology Healthcare

|February 8, 2013

Summary

This summary is machine-generated.

Navigating regulatory pathways for combination products like drug-eluting stents is complex. This discussion outlines the U.S. Food and Drug Administration's (FDA) strategies for these innovative medical products.

More Related Videos

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Related Experiment Videos

Last Updated: May 14, 2026

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Area of Science:

Biomedical Engineering
Regulatory Science
Pharmaceutical Sciences

Background:

Combination products merging drugs and devices, such as drug-eluting stents, present unique regulatory challenges.
Existing regulatory frameworks for standalone drugs or devices do not fully encompass these integrated products.

Purpose of the Study:

To elucidate the regulatory landscape for drug-device combination products.
To review the U.S. Food and Drug Administration's (FDA) initiatives in addressing the regulatory complexities of these products.

Main Methods:

Analysis of FDA guidance documents and policy statements.
Review of regulatory pathways for drug-eluting stents as a case example.
Discussion of the FDA's organizational and procedural adaptations.

Main Results:

The FDA has implemented specific strategies to manage the review and approval of combination products.
Clearer pathways are being established, though challenges remain in harmonizing drug and device regulations.

Conclusions:

The FDA is actively working to provide a more defined regulatory pathway for drug-device combination products.
Continued evolution of regulatory approaches is necessary to ensure timely access to safe and effective combination therapies.